Cara Therapeutics (CARA) Misses Q4 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. GOOGL
9. TSLA
10. CRWV

Go back to Cara Therapeutics (CARA) Misses Q4 EPS by 24c

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

March 6, 2023 4:01 PM EST

4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Companys share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative revenue of $16.6 million

Positive momentum across first four EU launches; Global rollout to accelerate with most EU countries launching in 2023

Phase 2/3 clinical program of oral difelikefalin in NP initiated in 2023; NDD CKD and AD programs tracking to expectations with internal readout from KIND 1 Part A expected in 2H23

Conference call today at 4:30 p.m. EST

STAMFORD,... More